Advertisement

Collaboration › Details
Exscientia–Evercore: investor conference, 202211 supply service Exscientia participates in Evercore ISI HealthCONx Conference 2022
![]() |
Period | 2022-11-29 |
![]() |
Partner, 1st | Exscientia plc (Nasdaq: EXAI) |
Group | Exscientia (Group) | |
![]() |
Product | Evercore ISI HealthCONx Conference 2022 DIGITAL |
Product 2 | AI-based drug discovery / AI-based drug development | |
Exscientia plc. (11/1/22). "Press Release: Exscientia to Present at Upcoming Investor Conferences in November". Oxford.
Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November:
> BofA Securities 2022 A.I. and Disruptive Tech Conference. Fireside chat (AI in Drug Discovery) on Wednesday, November 9, 2022, at 12:40 p.m. EST (5:40 p.m. GMT)
> 2022 Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November 16, 2022, in London, United Kingdom
> 5th Annual Evercore ISI HealthCONx Conference. Fireside chat onTuesday, November 29, 2022, at8:50 a.m. EST (1:50 p.m. GMT)
Live webcasts of the fireside chats will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
Investors:
Sara Sherman
investors@exscientia.ai
Media:
media@exscientia.ai
Record changed: 2022-11-08 |
Advertisement

More documents for Exscientia (Group)
- [1] Exscientia plc. (8/31/23). "Press Release: Exscientia to Present at Upcoming Investor Conferences in September". Oxford....
- [2] Exscientia plc. (3/14/23). "Press Release: Exscientia Announces Expansion of its Precision Oncology Pipeline". Oxford....
- [3] Exscientia plc. (3/7/23). "Press Release: Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform". Oxford & Berlin....
- [4] Exscientia plc. (11/3/22). "Press Release: Exscientia Expands Biologics Design Capability with Automated Laboratory". Oxford....
- [5] Exscientia plc. (11/1/22). "Press Release: Exscientia to Present at Upcoming Investor Conferences in November". Oxford....
- [6] Exscientia plc. (6/6/23). "Press Release: Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference". Oxford....
- [7] Exscientia plc. (1/7/22). "Press Release: Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines". Paris, Oxford & Boston, MA....
- [8] Exscientia plc. (10/5/21). "Press Release: Exscientia Announces Closing of $510.4 Million Aggregate Financing". Oxford....
- [9] Exscientia plc. (9/30/21). "Press Release: Exscientia Announces Pricing of $304.7 Million Upsized Initial Public Offering and $160.0 Million Concurrent Private Placements". Oxford....
- [10] Exscientia Ltd.. (9/8/21). "Press Release: Exscientia Enters $70M Collaboration to Develop Anti-viral Therapeutics against Coronavirus and other Viruses with Pandemic Potential"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top